PDF(Pubmed)
Abstract：
UNASSIGNED: The purpose of this study was to examine the patterns of use of oral aripiprazole treatment in children and adolescents diagnosed with autism spectrum disorder (ASD) at a university medical center in Korea.
UNASSIGNED: We retrospectively reviewed the medical records of 164 outpatient children and adolescents diagnosed with ASD by child and adolescent psychiatrists. Patient demographic characteristics, clinical features, age and dose of aripiprazole treatment, associated adverse events, and concomitant medications, etc. were evaluated.
UNASSIGNED: Aripiprazole treatment was initiated at a mean age of 7.64 years, at a mean initial dose of 1.15 mg. Methylphenidate was often co-administered with aripiprazole. The most commonly reported adverse effects were increased appetite and weight gain, which in some cases led to discontinuation of medication.
UNASSIGNED: A follow-up study is warranted to evaluate the efficacy and safety of aripiprazole treatment in Korean children and adolescents diagnosed with ASD, and it is crucial to consider their clinical characteristics and response to treatment in the evaluation.
UNASSIGNED: We retrospectively reviewed the medical records of 164 outpatient children and adolescents diagnosed with ASD by child and adolescent psychiatrists. Patient demographic characteristics, clinical features, age and dose of aripiprazole treatment, associated adverse events, and concomitant medications, etc. were evaluated.
UNASSIGNED: Aripiprazole treatment was initiated at a mean age of 7.64 years, at a mean initial dose of 1.15 mg. Methylphenidate was often co-administered with aripiprazole. The most commonly reported adverse effects were increased appetite and weight gain, which in some cases led to discontinuation of medication.
UNASSIGNED: A follow-up study is warranted to evaluate the efficacy and safety of aripiprazole treatment in Korean children and adolescents diagnosed with ASD, and it is crucial to consider their clinical characteristics and response to treatment in the evaluation.
摘要：
■这项研究的目的是检查在韩国一所大学医学中心诊断为自闭症谱系障碍（ASD）的儿童和青少年中使用口服阿立哌唑治疗的模式。
■我们回顾了由儿童和青少年精神科医生诊断为ASD的164名门诊儿童和青少年的医疗记录。患者人口学特征,临床特征,阿立哌唑治疗的年龄和剂量，相关不良事件，和伴随的药物，等。进行了评估。
■阿立哌唑治疗开始时的平均年龄为7.64岁，平均初始剂量为1.15mg。哌醋甲酯通常与阿立哌唑共同给药。最常见的不良反应是食欲增加和体重增加，在某些情况下导致停药。
■有必要进行随访研究，以评估阿立哌唑治疗在被诊断为ASD的韩国儿童和青少年中的疗效和安全性。在评估中考虑其临床特征和对治疗的反应至关重要。
■我们回顾了由儿童和青少年精神科医生诊断为ASD的164名门诊儿童和青少年的医疗记录。患者人口学特征,临床特征,阿立哌唑治疗的年龄和剂量，相关不良事件，和伴随的药物，等。进行了评估。
■阿立哌唑治疗开始时的平均年龄为7.64岁，平均初始剂量为1.15mg。哌醋甲酯通常与阿立哌唑共同给药。最常见的不良反应是食欲增加和体重增加，在某些情况下导致停药。
■有必要进行随访研究，以评估阿立哌唑治疗在被诊断为ASD的韩国儿童和青少年中的疗效和安全性。在评估中考虑其临床特征和对治疗的反应至关重要。
